Triathlon Medical Ventures Triathlon Medical Ventures
Triathlon Medical Ventures Triathlon Medical Ventures Triathlon Medical Ventures
Triathlon Medical Ventures - Homepage
Triathlon Medical Ventures - Team
Triathlon Medical Ventures - Investment Focus
Triathlon Medical Ventures - Investment Strategy
Triathlon Medical Ventures - Investment Criteria
Contact Triathlon Medical Ventures - Evaluation Process
Triathlon Medical Ventures - Portfolio
Triathlon Medical Ventures - News
Triathlon Medical Ventures - Links
Contact Contact Triathlon Medical Ventures

Triathlon Medical Ventures

 

 

 

 


Biopharmaceutical
AERPIO THERAPEUTICS, INC.
AKEBIA THERAPEUTICS, INC.
BIOVEX, INC.
CoLUCID PHARMACEUTICALS, INC.
ENDOCYTE
JUVENTAS THERAPEUTICS
KEREOS, INC.
SIRONRX THERAPEUTICS, INC.
TOLERA THERAPEUTICS, INC.
Medical Device
CELLERATION, INC.
EXPANDING ORTHOPEDICS, INC.
HYDROCISION, INC.
LONESTAR HEART, INC.
MITRALIGN, INC.
REMON MEDICAL TECHNOLOGIES, INC.
RENAL SOLUTIONS, INC.
SUTURTEK, INC.


Biopharmaceutical Portfolio


PORTFOLIO



AERPIO THERAPEUTICS, INC.
10151 Carver Road, Suite 205
Cincinnati, OH 45242-4760
Phone: (513) 618-0933
Fax: (513) 618-0950
www.aerpio.com

Aerpio Therapeutics is a new, clinical-stage biotechnology company focused on the development of novel small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Aerpio was created in a spin-out transaction from Akebia Therapeutics Aerpio's two lead programs include a Tie-2 activator for diabetic macular edema (DME) and vascular leak, and a Hypoxia-inducible Factor 1-Α (HIF1-Α) stabilizer for wound healing and the treatment of inflammatory bowel disease.

back to top
 


PORTFOLIO



AKEBIA THERAPEUTICS, INC.
245 First Street, Suite 1100
Cambridge, MA 02142
Phone: (617) 871-2098
Fax: (617) 871-2099
www.akebia.com

Akebia Therapeutics is a venture-backed ischemia and vascular biology company spun-out of Procter & Gamble. Akebia has in-licensed existing, high-quality drug development programs and assets from P&G. The two licensed drug development programs were initiated and have been maturing within P&G Pharmaceuticals for many years with significant investment and internal support from P&G scientists. The strategy is to develop novel therapeutics for patients based on the biology of Hypoxia-inducible factor (HIF) and to commercialize products for patients with kidney disease, beginning with AKB-6548 for patients with anemia secondary to chronic kidney disease (CKD).

Now public: AKBA

back to top
 


PORTFOLIO



BIOVEX, INC.
34 Commerce Way
Woburn, MA 01801
Phone: (781) 933-1409
Fax: (781) 933-6025
www.biovex.com

BioVex is a biotechnology company focused on the development of novel biologics for the treatment of cancer and infectious disease.

Biovex' lead product for the treatment of cancer is OncoVEXGM-CSF. OncoVEXGM-CSF is in Phase II clinical development and is currently being tested in clinical trials for melanoma, head and neck cancer and pancreatic cancer.

The company's lead product for the prevention of infectious disease is ImmunoVEXHSV2. ImmunoVEXHSV2 is a candidate vaccine for herpes simplex virus 2, the virus responsible for the symptoms of genital herpes. ImmunoVEXHSV2 is in late stage pre-clinical development and is expected to begin clinical testing during 2007.

The Company is based in Woburn, Massachusetts, with an R&D facility in Oxford, UK.

Acquired by Amgen

back to top
 


PORTFOLIO



CoLUCID PHARMACEUTICALS, INC.
902 N. Capitol Ave., Suite 302
Indianapolis, IN 46204
Phone: (919) 806-4304
Fax: (919) 806-4301
www.colucid.com

Colucid Pharmaceuticals, Inc. is a CNS-focused company based on the in-licensing and development of (1) a potent and selective small molecule that has the potential to be useful in the acute treatment and/or prevention of migraine headaches and (2) a bi-functional neuromodulator program that is a novel and proprietary chemistry technology platform that enables rapid synthesis of compounds which modulate multiple independent biochemical targets or pathways.

back to top


PORTFOLIO



ENDOCYTE
1205 Kent Ave.
West Lafayette, IN 47906
Phone: (765) 463-7175
Fax: (765) 463-9271
www.endocyte.com

Endocyte is developing receptor-targeted imaging and therapeutic agents for the diagnosis and treatment of cancer and autoimmune diseases. The company's novel technology platform uses vitamins such as folate (a derivative of vitamin B-12) which are over expressed in many types of cancers and autoimmune diseases. As a result, their imaging and therapeutic agents target and kill diseased cells while leaving healthy tissues relatively unaffected. The technology is based upon work performed by Dr. Philip S. Low at Purdue University.

Now public: ECYT

back to top


PORTFOLIO



JUVENTAS THERAPEUTICS
10265 Carnegie Avenue
Cleveland, OH 44106-2130
Phone: (216) 445-0830
Fax: (216) 455-6514
www.juventasinc.com

Juventas Therapeutics is a Cleveland Clinic spin-off biotechnology company focused on developing regenerative medicine for chronic heart failure. This potentially ground breaking product (SDF-1) attracts stem cells circulating in the blood to repair tissue damage resulting from a heart attack. The body naturally produces SDF-1 following trauma, like a heart attack, but it is produced too briefly to have a long term beneficial impact. However, by manufacturing SDF-1 and injecting it at the site of damage, the protein stays there longer and attracts the stem cells needed for tissue repair.

back to top
 


PORTFOLIO



KEREOS, INC.
4041 Forest Park Ave.
St. Louis, MO 63108
Phone: (314) 633-1879
Fax: (314) 633-1878
www.kereos.com

Kereos, Inc. develops targeted therapeutics and molecular imaging agents that detect and attack cancer and cardiovascular disease earlier and more specifically than previously possible. Because Kereos' targeted therapeutics seek out definitive disease biomarkers and carry powerful payloads of proven chemotherapeutics, their specificity and potency make them potentially more effective and less toxic in treating disease. Similarly, the specificity and unique capabilities of Kereos molecular imaging agents enable earlier and more definitive diagnosis of disease.

back to top


PORTFOLIO



SIRONRX THERAPEUTICS, INC.
10000 Cedar Avenue
Cleveland, OH 44106
Phone: (216) 455-5588
www.sironrx.com

SironRX Therapeutics is developing novel therapies exclusively licensed from Juventas Therapeutics and Cleveland Clinic that promote dermal wound repair and reduce scarring. Our lead product is a clinically tested biopharmaceutical that encodes Stromal cell-Derived Factor-1 (SDF-1). SDF-1 is key molecule responsible for activating natural repair processes after tissue injury through prevention of cell death and recruitment of stem cells to the damaged organ. Studies from several laboratories suggest the therapeutic potential of SDF-1 for treatment of a range of wounds such as post-surgical incisions, chronic diabetic ulcers and burns. Development of a cost-effective interactive wound therapy that can be topically administered at the site-of-injury or in chronic wound care settings with the potential to significantly improve function of the damaged tissue will have a major impact on the multi-billion dollar advanced wound management market.

back to top
 


PORTFOLIO



TOLERA THERAPEUTICS, INC.
4717 Campus Drive
Kalamazoo, MI 49008
Phone: (800) 695-1554
www.tolera.com

Tolera is a spin-off from the Cleveland Clinic and is building upon research initiated at the University of Kentucky and the Cleveland Clinic. Tolera is developing therapies for the immune suppression/modulation market that are both safer and more targeted solutions to reduce the risk of serious and toxic side effects. The company's selective therapeutics have the potential for creating a pipeline of therapeutic products with a broad application in human immune diseases.

back to top
 


Medical Device Portfolio


PORTFOLIO



CELLERATION, INC.
10250 Valley View Road, Suite 137
Eden Prairie, MN 55344
Phone: (952) 224-8700
Fax: (952) 224-8750
www.celleration.com

Celleration®, Inc. was founded to develop and commercialize its therapeutic ultrasound platform. The patented MIST Technology™ utilizes ultrasonic sound waves to produce an energized mist of sterile saline in a non-contact fashion for treatment of chronic wounds such as a diabetic foot ulcers.

back to top


PORTFOLIO



EXPANDING ORTHOPEDICS, INC.
17 West Pontotoc Avenue, Suite 200
Memphis, TN 38103
Phone: (770) 754-4246
Fax: (770) 783-1359
www.exortho.com

Expanding Orthopedics is a medical device company developing orthopedic implants that use expandable metal and polymer components in bone to add greater strength with reduced surgical intrusion. The company has a dual platform for spinal fusion and trauma surgeries. The first product is a pedicle screw that acts like a molly bolt by expanding inside to firmly hold the bone. The second product is surgical nail for fractures of long bones that has small thorns which grab and hold onto the bone. The devices are especially effective in patients with poor bone quality.

back to top
 


PORTFOLIO



HYDROCISION, INC.
22 Linnell Circle, Suite 102
Billerica, MA 01821
Phone: (978) 474-9300
Fax: (978) 600-5037
www.hydrocision.com

HydroCision is the leading developer, manufacturer, and marketer of fluid-jet based surgical tools for the spine market. Incorporated in 1994, HydroCision's proprietary fluidjet technology is the basis of a new surgical modality leveraging compelling features and offering application versatility. The company is currently developing a broad range of fluidjet-based products to meet the needs of spine specialists.

back to top
 


PORTFOLIO



LONESTAR HEART, INC. (FORMERLY CARDIO POLYMERS INC.)
26051 Merit Circle, Suite 102
Laguna Hills, CA 92653
Phone: (949) 215-3613
www.lonestarheartinc.com

LoneStar Heart, Inc. is a disease-focused company developing breakthrough therapies to preserve and restore adequate heart function in patients with Advanced Heart Failure (HF), a condition that affects millions of ageing patients worldwide. Applying the latest insights from bioengineering, mathematical modeling, molecular biology, and clinical research, the company is advancing a number of product candidates that combine practical and cost-effective solutions with superior clinical outcomes.

back to top
 


PORTFOLIO



MITRALIGN, INC.
3 Highwood Drive
Tewksbury, MA 01876
Phone: (978) 863-2400
Fax: (978) 858-0160
www.mitralign.com

Combining surgical precision with interventional therapy, Mitralign is developing an innovative, catheter-based method to treat mitral regurgitation that not only provides an alternative to open heart surgery but simulates the surgical repair technique.

back to top
 


PORTFOLIO



REMON MEDICAL TECHNOLOGIES, INC.
1000 Winter Street
Suite 3350
Waltham, MA 02451
www.remonmedical.com

Remon Medical Technologies, Inc. develops and commercializes smart, miniature implants which enable physicians to assess and treat a variety of medical conditions in a non-invasive manner. The Company's enabling technology utilizes wireless communications to exchange energy and data with miniature devices placed deep inside the body, in order to either monitor a variety of physiological parameters or to stimulate tissues and organs or to activate other devices, creating therapeutic responses. Remon's unique platform has broad applications for patient management, post-operative monitoring, nerve and tissue stimulation, and local drug delivery/release. Remon is currently focusing on a Congestive Heart Failure application.

Acquired by Boston Scientific

back to top


PORTFOLIO



RENAL SOLUTIONS, INC.
770 Commonwealth Drive, Suite 101
Warrendale, PA 15086
Phone: (724) 772-6900
www.renalsolutionsinc.com

Renal Solutions, Inc., is a medical device company developing a revolutionary solution for the home and acute dialysis market and has a distinct competitive advantage as the only provider of dialysis products utilizing sorbent-based toxin removal technology. Using sorbent dialysate regeneration and a unique pressure controlled blood movement system, hemodialysis can be delivered safely and cost effectively in the home or clinical environment. The Allient® Sorbent Hemodialysis System requires only 6 liters of tap water. This capability eliminates the need for complex technology to create a purified water source as with conventional dialysis technology. The Allient System is transportable and can be used anywhere 110V power and tap water can be accessed. Renal Solutions is a privately held company focused on providing revolutionary products and service for renal failure patients that improve quality of life and aide in the reduction of the total cost of treatment. The Allient System is pending FDA approval.

Acquired by Fresenius

back to top


PORTFOLIO



SUTURTEK, INC.
51 Middlesex Street
North Chelmsford, MA 01863
Phone: (978) 251-8088
Fax: (978) 251-8585
www.suturtek.com

SuturTek is a development stage company with a patented platform technology for a portfolio of products that precisely replicate traditional hand suturing techniques providing faster, easier, safer suturing in both currently sutured procedures as well as additional open and minimally invasive procedures.

back to top


 
Copyright © 2004 - Triathlon Medical Ventures - All Rights Reserved Web Site Credits Legal Notices & Privacy Policy